JP6660369B2 - 神経障害を治療する方法 - Google Patents

神経障害を治療する方法 Download PDF

Info

Publication number
JP6660369B2
JP6660369B2 JP2017501186A JP2017501186A JP6660369B2 JP 6660369 B2 JP6660369 B2 JP 6660369B2 JP 2017501186 A JP2017501186 A JP 2017501186A JP 2017501186 A JP2017501186 A JP 2017501186A JP 6660369 B2 JP6660369 B2 JP 6660369B2
Authority
JP
Japan
Prior art keywords
rats
dose
composition
patient
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017501186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519807A (ja
JP2017519807A5 (cg-RX-API-DMAC7.html
Inventor
ジョン ジャハンガー アラム，
ジョン ジャハンガー アラム，
Original Assignee
イーアイピー ファーマ， エルエルシー
イーアイピー ファーマ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーアイピー ファーマ， エルエルシー, イーアイピー ファーマ， エルエルシー filed Critical イーアイピー ファーマ， エルエルシー
Publication of JP2017519807A publication Critical patent/JP2017519807A/ja
Publication of JP2017519807A5 publication Critical patent/JP2017519807A5/ja
Application granted granted Critical
Publication of JP6660369B2 publication Critical patent/JP6660369B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017501186A 2014-07-09 2015-07-08 神経障害を治療する方法 Active JP6660369B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022586P 2014-07-09 2014-07-09
US62/022,586 2014-07-09
PCT/US2015/039539 WO2016007616A1 (en) 2014-07-09 2015-07-08 Methods for treating neurologic disorders

Publications (3)

Publication Number Publication Date
JP2017519807A JP2017519807A (ja) 2017-07-20
JP2017519807A5 JP2017519807A5 (cg-RX-API-DMAC7.html) 2018-08-16
JP6660369B2 true JP6660369B2 (ja) 2020-03-11

Family

ID=55064826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017501186A Active JP6660369B2 (ja) 2014-07-09 2015-07-08 神経障害を治療する方法

Country Status (5)

Country Link
US (1) US9579322B2 (cg-RX-API-DMAC7.html)
EP (1) EP3166610B1 (cg-RX-API-DMAC7.html)
JP (1) JP6660369B2 (cg-RX-API-DMAC7.html)
CN (3) CN106659723A (cg-RX-API-DMAC7.html)
WO (1) WO2016007616A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659723A (zh) 2014-07-09 2017-05-10 爱普制药有限责任公司 用于治疗神经病症的方法
JP6889493B2 (ja) * 2015-10-26 2021-06-18 イーアイピー ファーマ， エルエルシー 脳卒中からの回復のための方法および組成物
WO2017185073A1 (en) * 2016-04-21 2017-10-26 Eip Pharma, Llc Compositions and methods for treating dementia
US11466008B2 (en) 2017-09-18 2022-10-11 Eip Pharma, Llc Co-crystals of neflamapimod (VX-745)
DK3691620T3 (da) 2017-10-05 2022-10-03 Fulcrum Therapeutics Inc P38-kinaseinhibitor reducerer dux4- og downstream-gen-ekspression til behandling af fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019178153A1 (en) * 2018-03-12 2019-09-19 Eip Pharma, Llc Pharmaceutical formulations of neflamapimod
IL283069B2 (en) * 2018-11-20 2025-09-01 Sparrow Pharmaceuticals Inc Methods of administering corticosteroids
WO2020257333A1 (en) * 2019-06-18 2020-12-24 Opiant Pharmaceuticals, Inc. Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist
US11471437B2 (en) 2019-06-18 2022-10-18 Opiant Pharmaceuticals, Inc. Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist
EP3996712A4 (en) * 2019-07-12 2023-05-24 EIP Pharma, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF DEMENTIA WITH LEWY BODY
IL302666A (en) * 2020-11-06 2023-07-01 Eip Pharma Inc Treatment of gait dysfunction in neurodegenerative disease
CN113616795B (zh) * 2021-08-31 2023-06-20 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍
US20240363225A1 (en) * 2023-04-27 2024-10-31 Remepy Health Ltd Digital therapeutics for improved neuro-connectivity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
CN100571701C (zh) * 2002-12-24 2009-12-23 贝卢斯健康(国际）有限公司 治疗β淀粉样蛋白相关疾病的治疗性制品
US20050203111A1 (en) 2004-03-12 2005-09-15 Vvii Newco 2003, Inc. Compositions and methods for preventing and treating skin and hair conditions
CA2558439A1 (en) 2004-03-11 2005-10-06 Kythera Biopharmaceuticals, Inc. Compositions and methods for preventing and treating skin and hair conditions
WO2007054896A1 (en) 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
EP2041078A4 (en) 2006-06-23 2016-06-01 The Feinstein Inst Medical Res INHIBITORS OF THE ABETE SYNNUCLEINE AGGREGATION
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
CA2832309A1 (en) * 2011-04-08 2013-03-28 David Campbell 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of nervous system disorders and cancer
ES2773480T3 (es) * 2011-05-09 2020-07-13 Eip Pharma Llc Composiciones y métodos para tratar la enfermedad de Alzheimer
CN106659723A (zh) 2014-07-09 2017-05-10 爱普制药有限责任公司 用于治疗神经病症的方法

Also Published As

Publication number Publication date
CN113018300B (zh) 2025-11-25
CN106659723A (zh) 2017-05-10
JP2017519807A (ja) 2017-07-20
EP3166610B1 (en) 2022-11-02
US9579322B2 (en) 2017-02-28
CN113018300A (zh) 2021-06-25
EP3166610A4 (en) 2017-11-29
US20160008364A1 (en) 2016-01-14
CN114010641A (zh) 2022-02-08
EP3166610A1 (en) 2017-05-17
WO2016007616A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
JP6660369B2 (ja) 神経障害を治療する方法
CN103842362B (zh) 用于治疗阿尔茨海默氏病的组合物和方法
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
CN103547264B (zh) σ配体在与2型糖尿病相关的疼痛中的用途
KR102891465B1 (ko) 뇌졸중으로부터의 회복을 위한 방법 및 조성물
US9427439B1 (en) Methods and compositions for recovery from stroke
JP6959371B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニストの新たな使用
JP2019516699A (ja) 純粋な５−ｈｔ６受容体アンタゴニストとアセチルコリンエステラーゼ阻害剤の組合せ
JP6629464B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種類の組合せ
JP6606298B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニストのｎｍｄａ受容体アンタゴニストとの組合せ
KR20170106485A (ko) 요산 또는 통풍 질환의 예방 또는 치료
HK40068517A (en) Methods for treating neurologic disorders
HK1260485A1 (en) Methods and compositions for recovery from stroke
HK1260485B (en) Methods and compositions for recovery from stroke
HK1230184B (en) Compositions and methods for treating alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180706

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200207

R150 Certificate of patent or registration of utility model

Ref document number: 6660369

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250